(Q43993343)

28 November 2017

title

Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion (English)

1 reference

28 November 2017

1 reference

K M Lee

1

1 reference

28 November 2017

Sung Won Cho

2

1 reference

28 November 2017

S W Kim

3

1 reference

28 November 2017

H J Kim

4

1 reference

28 November 2017

K B Hahm

5

1 reference

28 November 2017

J H Kim

6

1 reference

28 November 2017

publication date

1 May 2002

1 reference

Journal of Viral Hepatitis

28 November 2017

published in

1 reference

28 November 2017

volume

9

1 reference

28 November 2017

issue

3

1 reference

28 November 2017

page(s)

208-212

1 reference

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00357.X

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00357.X

Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00357.X

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00357.X

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00357.X

Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00357.X

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00357.X

Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00357.X

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00357.X

LONG-TERM FOLLOW-UP IN A RANDOMISED CONTROLLED TRIAL OF RECOMBINANT α2-INTERFERON IN CHINESE PATIENTS WITH CHRONIC HEPATITIS B INFECTION

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2002.00357.X

10.1046/J.1365-2893.2002.00357.X

21 January 2018

Identifiers

DOI

1 reference

28 November 2017

1 reference